BioShin’s $60 Million Series A Preferred Equity Financing

Locke Lord LLP advised Biohaven Pharmaceutical Holding Company on the deal.

Biohaven Pharmaceutical Holding Company announced a $60 million Series A Preferred equity financing of BioShin Limited, Biohaven’s subsidiary that is scheduled to exploit Biohaven intellectual property in the Asia-Pacific territory. The financing was led by OrbiMed Asia, with participation from Cormorant Asset Management LLC, HBM Healthcare Investments Ltd, Surveyor Capital (a Citadel Company) and Suvretta Capital Management, LLC. BioShin will advance Biohaven’s clinical portfolio in the Asia-Pacific region, addressing migraine, neurologic and neuropsychiatric diseases.

The Locke Lord team was led by Douglas Gray (Picture), Baker Coon, Kathrine Morin, Ralph Loren, Lori Basilico, Stephen Murphy and Jaremi Chilton.

Involved fees earner: Lori Basilico – Locke Lord; Jaremi Chilton – Locke Lord; Baker Coon – Locke Lord; Douglas Gray – Locke Lord; Ralph Loren – Locke Lord; Kathrine Morin – Locke Lord; Stephen Murphy – Locke Lord;

Law Firms: Locke Lord;

Clients: Biohaven Pharmaceutical Holding Company Limited; BioShin Limited ;

Author: Ambrogio Visconti